Belpointe Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$362K Buy
4,855
+1,146
+31% +$84.4K 0.01% 842
2026
Q2
$237K Buy
+3,709
New +$192K 0.01% 988
2023
Q2
– Sell
-1,200
Closed -$12.9K – 2070
2023
Q1
$12.9K Hold
1,200
– – ﹤0.01% 2567
2022
Q4
$18K Buy
+1,200
New +$17.5K ﹤0.01% 2260

Other funds holding KNSA

Belpointe Asset Management's KNSA Position: Q3 2026 in Review

Belpointe Asset Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 31% in Q3 2026, buying an estimated $84.4K and bringing the position to 4,855 shares worth $362K. The position accounts for 0.01% of the portfolio, ranked #842.

Belpointe Asset Management first reported a position in KNSA in Q4 2022 and has held it in 4 quarters since. 248 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Belpointe Asset Management held 4,855 shares of Kiniksa Pharmaceuticals worth $362K as of Q3 2026.
  • Belpointe Asset Management bought 1,146 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $84.4K.
  • Kiniksa Pharmaceuticals made up 0.01% of Belpointe Asset Management's portfolio in Q3 2026, its #842 holding.
  • Belpointe Asset Management first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
  • 248 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Belpointe Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.